LONDON, April 24, 2018 /PRNewswire/ --
Stephen M Twigg, Mahmood R Kazemi, Maria E Craig; US Endocrinology, 2017;13(2):57-62 https://doi.org/10.17925/USE.2017.13.02.57
Published recently in US Endocrinology, the peer-reviewed journal from touchENDOCRINOLOGY, Stephen M Twigg et al discuss established methods of self-monitoring of glucose levels include capillary self-monitoring of blood glucose (SMBG) and interstitial continuous glucose monitoring (CGM). Flash CGM is a novel form of self-monitoring that provides on-demand continuous interstitial glucose profiles. The purpose of this article is to critically review the recent outcome data from randomized controlled trials that assessed the efficacy and safety of flash CGM to replace routine SMBG in diabetes management. Methods: Two recent six-month, prospective, multicenter, randomized controlled trials in type 1 (IMPACT; NCT02232698) and type 2 (REPLACE; NCT02082184) diabetes compared flash CGM with SMBG under otherwise usual care conditions. The trials did not use a prescribed treatment algorithm based on self-monitoring of glucose. Results: Both trials demonstrated that the time spent in hypoglycemia over a 24-hour period, as well as overnight, was markedly reduced by flash CGM without deterioration in glycated hemoglobin (A1C) levels. In IMPACT there was a 38% reduction in time in hypoglycemia with flash CGM versus SMBG, and in REPLACE there was a 43% reduction in time in hypoglycemia with flash CGM compared with SMBG. Moreover, patient satisfaction improved with flash CGM, usage adherence rates were high, and flash CGM was well tolerated. Conclusions: The findings from these trials suggest that improved care outcomes can be achieved when flash CGM is integrated into current established clinical care paradigms. Flash CGM provides important advantages over SMBG that are likely to be applicable to real-world care of individuals with differing forms of diabetes requiring intensive insulin treatment.
The full peer-reviewed, open-access article is available here:
Disclosure: Stephen M Twigg is an advisory panel member and is on the speaker's bureau for Abbott Diabetes Care, Astra Zeneca, Novo Nordisk Australia, Sanofi- Aventis, Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals. He is on the speaker's bureau only for Takeda Pharmaceutical Company Limited, Merck Sharp & Dohme Corporation, Novartis Pharmaceuticals Corporation, and Servier. Mahmood R Kazemi is an employee of Abbott Diabetes Care. Maria E Craig is an advisory panel member for Abbott Diabetes Care, and is on the speaker's bureau for Novo Nordisk Australia, Pfizer Australia. Abbott Diabetes Care has contracted with Watermeadow Medical (UK) to manage and prepare this manuscript.
touchENDOCRINOLOGY (a division of Touch Medical Media) publishes
US Endocrinology, a peer-reviewed, open access, bi-annual journal specializing in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of endocrinology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals.
Touch Medical Media is a trading name of Touch Digital Media Limited, a private limited company registered in England and Wales at The White House Mill Road, Goring, Reading, England, RG8 9DD with registered number 08197142.
For inquires please contact:
Nicola Cartridge - Editorial Director
Leading the Debate on the Advances in Healthcare